The DOI matches its Crossref record; 135 of the 135 references it cites were found in a registry or an index.
PI3K/Akt/mTOR and Ras/Raf/MEK/ERK signaling pathways inhibitors as anticancer agents: Structural and pharmacological perspectives
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Siegel, R., Naishadham, D., & Jemal, A. (2012) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20138 · Cited by 10,679
mTOR Signaling in Growth Control and Disease
Laplante, M., & Sabatini, D. M. (2012) · Cell · doi:10.1016/j.cell.2012.03.017 · Cited by 8,509
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
The phosphatidylinositol 3-Kinase–AKT pathway in human cancer
Vivanco, I., & Sawyers, C. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc839 · Cited by 6,056
TOR signaling in growth and metabolism
Wullschleger, S., Loewith, R., & Hall, M. N. (2006) · Cell · doi:10.1016/j.cell.2006.01.016 · Cited by 5,787
Li, J., Yen, C., Liaw, D., Podsypanina, K., Bose, S., Wang, S. I., Puc, J., Miliaresis, C., Rodgers, L., McCombie, R., et al. (1997) · Science · doi:10.1126/science.275.5308.1943 · Cited by 4,785
TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling
Inoki, K., Li, Y., Zhu, T., Wu, J., & Guan, K.-L. (2002) · Nature Cell Biology · doi:10.1038/ncb839 · Cited by 3,083
Defining the role of mTOR in cancer
Guertin, D. A., & Sabatini, D. M. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.05.008 · Cited by 2,833
Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer
Roberts, P. J., & Der, C. J. (2007) · Oncogene · doi:10.1038/sj.onc.1210422 · Cited by 2,788
Targeting PI3K signalling in cancer: opportunities, challenges and limitations
Engelman, J. A. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2664 · Cited by 2,445
PI3K/Akt signalling pathway and cancer
Vara, J. Á. F., Casado, E., de Castro, J., Cejas, P., Belda-Iniesta, C., & González-Barón, M. (2004) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2003.07.007 · Cited by 2,443
Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance
McCubrey, J. A., Steelman, L. S., Chappell, W. H., Abrams, S. L., Wong, E. W. T., Chang, F., Lehmann, B., Terrian, D. M., Milella, M., Tafuri, A., et al. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2006.10.001 · Cited by 2,284
Protein kinases — the major drug targets of the twenty-first century?
Cohen, P. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd773 · Cited by 2,186
Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
Flaherty, K. T., Robert, C., Hersey, P., Nathan, P., Garbe, C., Milhem, M., Demidov, L. V., Hassel, J. C., Rutkowski, P., Mohr, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203421 · Cited by 2,160
Glycogen synthase kinase-3β regulates cyclin D1 proteolysis and subcellular localization
Diehl, J. A., Cheng, M., Roussel, M. F., & Sherr, C. J. (1998) · Genes & Development · doi:10.1101/gad.12.22.3499 · Cited by 2,130
The PI3K‒PDK1 connection: more than just a road to PKB
Vanhaesebroeck, B., & Alessi, D. R. (2000) · Biochemical Journal · doi:10.1042/0264-6021:3460561 · Cited by 1,644
Scansite 2.0: proteome-wide prediction of cell signaling interactions using short sequence motifs
Obenauer, J. C. (2003) · Nucleic Acids Research · doi:10.1093/nar/gkg584 · Cited by 1,596
Manning, B. D., Tee, A. R., Logsdon, M. N., Blenis, J., & Cantley, L. C. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00568-3 · Cited by 1,555
Targeting PI3K/Akt/mTOR Signaling in Cancer
Porta, C., Paglino, C., & Mosca, A. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00064 · Cited by 1,485
Jacinto, E., Facchinetti, V., Liu, D., Soto, N., Wei, S., Jung, S. Y., Huang, Q., Qin, J., & Su, B. (2006) · Cell · doi:10.1016/j.cell.2006.08.033 · Cited by 1,410
Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group
Flaherty, K. T., Robert, C., Hersey, P., Nathan, P., Garbe, C., Milhem, M. M., Демидов, Л. В., Hassel, J. C., Rutkowski, P. L., Mohr, P., et al. (2012) · Zurich Open Repository and Archive (University of Zurich) · doi:10.5167/uzh-63198 · Cited by 1,330
Sukhatme, V. P., Cao, X., Chang, L. C., Tsai-Morris, C.-H., Stamenkovich, D., Ferreira, P. C. P., Cohen, D. R., Edwards, S. A., Shows, T. B., Curran, T., et al. (1988) · Cell · doi:10.1016/0092-8674(88)90485-0 · Cited by 1,250
The RAF proteins take centre stage
Wellbrock, C., Karasarides, M., & Marais, R. (2004) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1498 · Cited by 1,228
Chang, F., Lee, J. T., Navolanic, P. M., Steelman, L. S., Shelton, J. G., Blalock, W. L., Franklin, R. A., & McCubrey, J. A. (2003) · Leukemia · doi:10.1038/sj.leu.2402824 · Cited by 1,176
Role of Translocation in the Activation and Function of Protein Kinase B
Andjelkovic, M., Alessi, D. R., Meier, R., Fernandez, A., Lamb, N. J. C., Frech, M., Cron, P., Cohen, P., Lucocq, J. M., & Hemmings, B. A. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.50.31515 · Cited by 1,051
Razandi, M., Pedram, A., Greene, G. L., & Levin, E. R. (1999) · Molecular Endocrinology · doi:10.1210/mend.13.2.0239 · Cited by 1,040
Targeting PI3K/mTOR Signaling in Cancer
Arcaro, A. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00084 · Cited by 1,024
Akt regulates growth by directly phosphorylating Tsc2
Potter, C. J., Pedraza, L. G., & Xu, T. (2002) · Nature Cell Biology · doi:10.1038/ncb840 · Cited by 959
Phosphoinositide 3-kinases: A conserved family of signal transducers
Vanhaesebroeck, B., Leevers, S. J., Panayotou, G., & Waterfield, M. D. (1997) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(97)01061-x · Cited by 954
NAVÉ, B. T., Ouwens, D. M., Withers, D. J., Alessi, D. R., & Shepherd, P. R. (1999) · Biochemical Journal · doi:10.1042/0264-6021:3440427 · Cited by 932
The Biology and Clinical Relevance of the PTEN Tumor Suppressor Pathway
Sansal, I., & Sellers, W. R. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.02.141 · Cited by 921
Scaffold Proteins: Hubs for Controlling the Flow of Cellular Information
Good, M. C., Zalatan, J. G., & Lim, W. A. (2011) · Science · doi:10.1126/science.1198701 · Cited by 885
Signaling by Distinct Classes of Phosphoinositide 3-Kinases
Vanhaesebroeck, B., & Waterfield, M. D. (1999) · Experimental Cell Research · doi:10.1006/excr.1999.4701 · Cited by 853
Garnett, M. J., & Marais, R. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.09.022 · Cited by 799
Bcl-2 Targets the Protein Kinase Raf-1 to Mitochondria
Wang, H.-G., Rapp, U. R., & Reed, J. C. (1996) · Cell · doi:10.1016/s0092-8674(00)81383-5 · Cited by 766
Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway
Polivka, J., & Janku, F. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.12.004 · Cited by 765
Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance
McCubrey, J. A., Steelman, L. S., Abrams, S. L., Lee, J. T., Chang, F., Bertrand, F. E., Navolanic, P. M., Terrian, D. M., Franklin, R. A., D’Assoro, A. B., et al. (2006) · Advances in Enzyme Regulation · doi:10.1016/j.advenzreg.2006.01.004 · Cited by 664
Smith, R. A., Cokkinides, V., Brooks, D., Saslow, D., & Brawley, O. W. (2010) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20063 · Cited by 660
Reed, J. C. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd726 · Cited by 643
Targeting the mTOR Signaling Network for Cancer Therapy
Meric-Bernstam, F., & Gonzalez-Angulo, A. M. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.0766 · Cited by 639
Raf meets Ras: completing the framework of a signal transduction pathway
Avruch, J., Zhang, X.-F., & Kyriakis, J. M. (1994) · Trends in Biochemical Sciences · doi:10.1016/0968-0004(94)90005-1 · Cited by 577
Ras Protein Farnesyltransferase: A Strategic Target for Anticancer Therapeutic Development
Rowinsky, E. K., Windle, J. J., & Von Hoff, D. D. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.11.3631 · Cited by 537
Brazil, D. P., Park, J., & Hemmings, B. A. (2002) · Cell · doi:10.1016/s0092-8674(02)01083-8 · Cited by 537
Yang, Q., Inoki, K., Ikenoue, T., & Guan, K.-L. (2006) · Genes & Development · doi:10.1101/gad.1461206 · Cited by 517
Chappell, W. H., Steelman, L. S., Long, J. M., Kempf, R. C., Abrams, S. L., Franklin, R. A., Bäsecke, J., Stivala, F., Donia, M., Fagone, P., et al. (2011) · Oncotarget · doi:10.18632/oncotarget.240 · Cited by 510
Structure and biological activity of v-raf, a unique oncogene transduced by a retrovirus.
Rapp, U. R., Goldsborough, M. D., Mark, G. E., Bonner, T. I., Groffen, J., Reynolds, F. H., & Stephenson, J. R. (1983) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.80.14.4218 · Cited by 483
Picking the Point of Inhibition: A Comparative Review of PI3K/AKT/mTOR Pathway Inhibitors
Dienstmann, R., Rodon, J., Serra, V., & Tabernero, J. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0639 · Cited by 462
Radiotherapy and the Tumor Stroma: The Importance of Dose and Fractionation
Hellevik, T., & Martinez-Zubiaurre, I. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00001 · Cited by 442
FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia
Stirewalt, D. L., Kopecky, K. J., Meshinchi, S., Appelbaum, F. R., Slovak, M. L., Willman, C. L., & Radich, J. P. (2001) · Blood · doi:10.1182/blood.v97.11.3589 · Cited by 431
Apoptosis-based therapies for hematologic malignancies
Reed, J. C., & Pellecchia, M. (2005) · Blood · doi:10.1182/blood-2004-07-2761 · Cited by 402
Inhibition of Ras for Cancer Treatment: The Search Continues
Baines, A. T., Xu, D., & Der, C. J. (2011) · Future Medicinal Chemistry · doi:10.4155/fmc.11.121 · Cited by 382
Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer
Saini, K. S., Loi, S., de Azambuja, E., Metzger-Filho, O., Saini, M. L., Ignatiadis, M., Dancey, J. E., & Piccart-Gebhart, M. J. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2013.03.009 · Cited by 374
Powell, D. J., Hajduch, E., Kular, G., & Hundal, H. S. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.21.7794-7808.2003 · Cited by 370
Plasma membrane estrogen receptors
Levin, E. R. (2009) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2009.06.009 · Cited by 365
Medical physiology : principles for clinical medicine
Rhoades, R. A., & Bell, D. R. (1995) · Cited by 332
Fibronectin and Its Integrin Receptors in Cancer
(1999) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)60772-1 · Cited by 330
Schmitz, K. J., Wohlschlaeger, J., Lang, H., Sotiropoulos, G. C., Malago, M., Steveling, K., Reis, H., Cicinnati, V. R., Schmid, K. W., & Baba, H. A. (2008) · Journal of Hepatology · doi:10.1016/j.jhep.2007.08.018 · Cited by 309
Role of PI3K/AKT/mTOR signaling in the cell cycle progression of human prostate cancer
Gao, N., Zhang, Z., Jiang, B.-H., & Shi, X. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2003.09.132 · Cited by 275
MEK in cancer and cancer therapy
Neuzillet, C., Tijeras-Raballand, A., de Mestier, L., Cros, J., Faivre, S., & Raymond, E. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.10.001 · Cited by 264
Isotype-Specific Functions of Raf Kinases
Hagemann, C., & Rapp, U. R. (1999) · Experimental Cell Research · doi:10.1006/excr.1999.4689 · Cited by 261
Tyrosine Phosphorylation of p85 Relieves Its Inhibitory Activity on Phosphatidylinositol 3-Kinase
Cuevas, B. D., Lu, Y., Mao, M., Zhang, J., LaPushin, R., Siminovitch, K., & Mills, G. B. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m100556200 · Cited by 256
MEK/ERK signaling contributes to the maintenance of human embryonic stem cell self-renewal
Li, J., Wang, G., Wang, C., Zhao, Y., Zhang, H., Tan, Z., Song, Z., Ding, M., & Deng, H. (2007) · Differentiation · doi:10.1111/j.1432-0436.2006.00143.x · Cited by 248
Raf kinase as a target for anticancer therapeutics
Sridhar, S. S., Hedley, D., & Siu, L. L. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-04-0297 · Cited by 245
Targeting the PI3-Kinase/Akt/mTOR Signaling Pathway
Hassan, B., Akcakanat, A., Holder, A. M., & Meric-Bernstam, F. (2013) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2013.06.008 · Cited by 225
Recent progress in targeting the Raf/MEK/ERK pathway with inhibitors in cancer drug discovery
THOMPSON, N., & LYONS, J. (2005) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2005.04.007 · Cited by 214
Targeting the PI3K-AKT-mTOR signaling network in cancer
Khan, K. H., Yap, T. A., Yan, L., & Cunningham, D. (2013) · Chinese Journal of Cancer · doi:10.5732/cjc.013.10057 · Cited by 213
Kavitha, K., Kowshik, J., Kishore, T. K. K., Baba, A. B., & Nagini, S. (2013) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2013.05.032 · Cited by 209
PIK3CA/PTEN Mutations and Akt Activation As Markers of Sensitivity to Allosteric mTOR Inhibitors
Meric-Bernstam, F., Akcakanat, A., Chen, H., Do, K.-A., Sangai, T., Adkins, F., Gonzalez-Angulo, A. M., Rashid, A., Crosby, K., Dong, M., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2123 · Cited by 208
Reversal of Raf-1 Activation by Purified and Membrane-Associated Protein Phosphatases
Dent, P., Jelinek, T., Morrison, D. K., Weber, M. J., & Sturgill, T. W. (1995) · Science · doi:10.1126/science.7604263 · Cited by 197
Hayakawa, M., Kaizawa, H., Moritomo, H., Koizumi, T., Ohishi, T., Okada, M., Ohta, M., Tsukamoto, S.-I., Parker, P., Workman, P., et al. (2006) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2006.06.046 · Cited by 194
Wang, L., Harris, T. E., & Lawrence, J. C. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m800723200 · Cited by 186
Strategies for co-targeting the PI3K/AKT/mTOR pathway in NSCLC
Heavey, S., O’Byrne, K. J., & Gately, K. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2013.08.006 · Cited by 178
Jakubíková, J., Sedlák, J., Mithen, R., & Bao, Y. (2005) · Biochemical Pharmacology · doi:10.1016/j.bcp.2005.03.015 · Cited by 175
Polier, G., Neumann, J., Thuaud, F., Ribeiro, N., Gelhaus, C., Schmidt, H., Giaisi, M., Köhler, R., Müller, W. W., Proksch, P., et al. (2012) · Chemistry & Biology · doi:10.1016/j.chembiol.2012.07.012 · Cited by 166
Asati, V., Mahapatra, D. K., & Bharti, S. K. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.10.025 · Cited by 165
Self-citationCotargeting survival signaling pathways in cancer
Grant, S. (2008) · Journal of Clinical Investigation · doi:10.1172/jci36898 · Cited by 164
Peterson, Q. P., Hsu, D. C., Goode, D. R., Novotny, C. J., Totten, R. K., & Hergenrother, P. J. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900722z · Cited by 156
Targeting the PI3K/AKT/mTOR pathway: potential for lung cancer treatment
Cheng, H., Shcherba, M., Pendurti, G., Liang, Y., Piperdi, B., & Perez-Soler, R. (2014) · Lung Cancer Management · doi:10.2217/lmt.13.72 · Cited by 156
Martelli, A. M., Evangelisti, C., Chiarini, F., Grimaldi, C., Cappellini, A., Ognibene, A., & McCubrey, J. A. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2010.04.005 · Cited by 150
Zinda, M. J., Johnson, M., Paul, J., Horn, C. L., Konicek, B. W., Lü, Z., Sandusky, G. E., Thomas, J. E., Neubauer, B. L., Lai, M. T., et al. (2001) · PubMed · Cited by 148
Lange, C. A., & Yee, D. (2011) · Endocrine Related Cancer · doi:10.1530/erc-11-0112 · Cited by 148
Cotargeting survival signaling pathways in cancer
Grant, S. (2008) · Journal of Clinical Investigation · doi:10.1172/jci36898e1 · Cited by 142
Cucurbitacin B inhibits STAT3 and the Raf/MEK/ERK pathway in leukemia cell line K562
Chan, K. T., Li, K., Liu, S. L., Chu, K. H., Toh, M., & Xie, W. D. (2009) · Cancer Letters · doi:10.1016/j.canlet.2009.07.015 · Cited by 138
Bottazzi, M. E., Zhu, X., Böhmer, R. M., & Assoian, R. K. (1999) · The Journal of Cell Biology · doi:10.1083/jcb.146.6.1255 · Cited by 135
Differential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanoma
Carlino, M. S., Todd, J. R., Gowrishankar, K., Mijatov, B., Pupo, G. M., Fung, C., Snoyman, S., Hersey, P., Long, G. V., Kefford, R. F., et al. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.01.003 · Cited by 127
Conus, N. M., Hannan, K. M., Cristiano, B. E., Hemmings, B. A., & Pearson, R. B. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m203387200 · Cited by 114
Aksamitiene, E., Kholodenko, B. Ν., Kölch, W., Hoek, J. B., & Kiyatkin, A. B. (2010) · Cellular Signalling · doi:10.1016/j.cellsig.2010.05.006 · Cited by 113
Liu, Z., Chen, S., Boyle, S., Zhu, Y., Zhang, A. J., Piwnica-Worms, D. R., Ilagan, M. X. G., & Kopan, R. (2013) · Developmental Cell · doi:10.1016/j.devcel.2013.05.022 · Cited by 112
Role of PI3K/Akt/mTOR and MEK/ERK pathway in Concanavalin A induced autophagy in HeLa cells
Roy, B., Pattanaik, A. K., Das, J., Bhutia, S. K., Behera, B., Singh, P., & Maiti, T. K. (2014) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2014.01.003 · Cited by 111
Raf kinases: Oncogenesis and drug discovery
Schreck, R., & Rapp, U. R. (2006) · International Journal of Cancer · doi:10.1002/ijc.22144 · Cited by 110
Porta, C., & Figlin, R. A. (2009) · The Journal of Urology · doi:10.1016/j.juro.2009.08.085 · Cited by 110
Tang, C., & Tsai, C.-C. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.11.013 · Cited by 109
Liu, K., Rao, W., Parikh, H. I., Li, Q., Guo, T. L., Grant, S., Kellogg, G. E., & Zhang, S. (2011) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2011.10.031 · Cited by 106
Phosphoinositide-Dependent Phosphorylation of PDK1 Regulates Nuclear Translocation
Scheid, M. P., Parsons, M., & Woodgett, J. R. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.6.2347-2363.2005 · Cited by 89
Sheppard, K. E., Cullinane, C. M., Hannan, K. M., Wall, M., Chan, J., Barber, F., Foo, J. H., Cameron, D. P., Neilsen, A., Ng, P. Y., et al. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.08.007 · Cited by 88
Regulation of Phosphoinositide 3-Kinase by Its Intrinsic Serine Kinase Activity In Vivo
Foukas, L. C., Beeton, C. A., Jensen, J., Phillips, W. A., & Shepherd, P. R. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.3.966-975.2004 · Cited by 81
Nantel, A., Huber, M., & Thomas, D. Y. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.50.35719 · Cited by 80
Selective GRB2 SH2 inhibitors as anti-Ras therapy
Gay, B., Suarez, S., Caravatti, G., Furet, P., Meyer, T., & Schoepfer, J. G. (1999) · International Journal of Cancer · Cited by 74
Isoform-Specific Localization of A-RAF in Mitochondria
Yuryev, A., Ono, M., Goff, S. A., Macaluso, F., & Wennogle, L. P. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.13.4870-4878.2000 · Cited by 64
Sánchez-Hernández, I., Baquero, P., Calleros, L., & Chiloeches, A. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.09.037 · Cited by 61
Luo, Q., Gu, Y., Zheng, W., Wu, X., Gong, F., Gu, L., Sun, Y., & Xu, Q. (2011) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2010.12.011 · Cited by 60
Ripple, M. O., Kim, N.-J., & Springett, R. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.438945 · Cited by 60
Irons, R., & Stillman, W. S. (1996) · Environmental Health Perspectives · doi:10.1289/ehp.961041239 · Cited by 59
Sambade, M. J., Camp, J. T., Kimple, R. J., Sartor, C. I., & Shields, J. M. (2009) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2009.09.006 · Cited by 56
Activation of the PI3K–AKT–mTOR signaling pathway promotes DEHP-induced Hep3B cell proliferation
Chen, X., Qin, Q., Zhang, W., Zhang, Y., Zheng, H., Liu, C., Yang, Y., Xiong, W., & Yuan, J. (2013) · Food and Chemical Toxicology · doi:10.1016/j.fct.2013.06.016 · Cited by 54
Role of the Raf/MEK/ERK and the PI3K/Akt(PKB) pathways in fibroblast senescence
Lorenzini, A., Tresini, M., Mawal-Dewan, M., Frisoni, L., Zhang, H., Allen, R. G., Sell, C., & Cristofalo, V. J. (2002) · Experimental Gerontology · doi:10.1016/s0531-5565(02)00133-x · Cited by 51
Hong, S., Kim, J. H., Lin, M.-F., & Park, J. (2011) · Experimental Cell Research · doi:10.1016/j.yexcr.2011.08.008 · Cited by 50
Rationale for Targeting the PI3K/Akt/mTOR Pathway in Myeloproliferative Neoplasms
Bartalucci, N., Guglielmelli, P., & Vannucchi, A. M. (2013) · Clinical Lymphoma Myeloma and Leukemia · doi:10.1016/j.clml.2013.07.011 · Cited by 49
Even stressed cells are individuals: second messengers of free radicals in pathophysiology of cancer
Jaganjac, M., Čaćev, T., Gašparović, A. Č., Kapitanović, S., Gall‐Tros̆elj, K., & Žarković, N. (2012) · Croatian Medical Journal · doi:10.3325/cmj.2012.53.304 · Cited by 45
Raf Kinase Inhibitors in Oncology
Strumberg, D., & Seeber, S. (2005) · Oncology Research and Treatment · doi:10.1159/000083373 · Cited by 44
Zhu, J., Balan, V., Bronisz, A., Balan, K., Sun, H., Leicht, D. T., Luo, Z., Qin, J., Avruch, J., & Tzivion, G. (2005) · Molecular Biology of the Cell · doi:10.1091/mbc.e05-02-0090 · Cited by 43
Alternative dosing of dual PI3K and MEK inhibition in cancer therapy
Jokinen, E., Laurila, N., & Koivunen, J. P. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-612 · Cited by 42
Li, Q., Wu, J., Zheng, H., Liu, K., Guo, T. L., Liu, Y., Eblen, S. T., Grant, S., & Zhang, S. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.06.030 · Cited by 40
Edwards, S. A., Darland, T., Sosnowski, R. G., Samuels, M., & Adamson, E. D. (1991) · Developmental Biology · doi:10.1016/0012-1606(91)90327-y · Cited by 38
Synergistic inhibition of thyroid cancer by suppressing MAPK/PI3K/AKT pathways
Kandil, E. H., Tsumagari, K., Ma, J., Elmageed, Z. Y. A., Li, X., Slakey, D. P., Mondal, D., & Abdel‐Mageed, A. B. (2013) · Journal of Surgical Research · doi:10.1016/j.jss.2013.03.052 · Cited by 38
Robbs, B. K., Lucena, P. I., & Viola, J. P. B. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2013.04.003 · Cited by 37
Structure-based design of thienobenzoxepin inhibitors of PI3-kinase
Staben, S. T., Siu, M., Goldsmith, R. A., Olivero, A. G., Do, S., Burdick, D. J., Heffron, T. P., Dotson, J., Sutherlin, D. P., Zhu, B., et al. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.04.124 · Cited by 37
Bcl-2-Regulated Calcium Signals as Common Mediators of Both Apoptosis and Autophagy
Swerdlow, S., & Distelhorst, C. (2007) · Developmental Cell · doi:10.1016/j.devcel.2007.01.008 · Cited by 35
Targeting Raf/MEK/ERK pathway in pituitary adenomas
Zhang, S., Feng, W., Dongsheng, G., & Lei, T. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.11.002 · Cited by 35
Structure-based optimization of pyrazolo-pyrimidine and -pyridine inhibitors of PI3-kinase
Staben, S. T., Heffron, T. P., Sutherlin, D. P., Bhat, S. R., Castanedo, G. M., Chuckowree, I., Dotson, J., Folkes, A. J., Friedman, L. S., Lee, L. B., et al. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.08.067 · Cited by 31
Discovery of triazine-benzimidazoles as selective inhibitors of mTOR
Peterson, E. A., Andrews, P. S., Be, X., Boezio, A. A., Bush, T. L., Cheng, A. C., Coats, J. R., Colletti, A. E., Copeland, K. W., DuPont, M. M., et al. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.02.007 · Cited by 30
Yun, S., Jung, K. H., Lee, H., Son, M. K., Seo, J.-H., YAN, H. H., Park, B. H., Hong, S., & Hong, S. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.01.007 · Cited by 29
Novel imidazolopyrimidines as dual PI3-Kinase/mTOR inhibitors
Venkatesan, A. M., Dehnhardt, C. M., Chen, Z., Santos, E. D., dos Santos, O., Bursavich, M. G., Gilbert, A. M., Ellingboe, J. W., Ayral‐Kaloustian, S., Khafizova, G., et al. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.11.057 · Cited by 28
Ripple, M. O., Kim, N.-J., & Springett, R. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.430082 · Cited by 27
Scaffold State Switching Amplifies, Accelerates, and Insulates Protein Kinase C Signaling
Greenwald, E. C., Redden, J. M., Dodge‐Kafka, K. L., & Saucerman, J. J. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.497941 · Cited by 27
NBS1 is required for IGF-1 induced cellular proliferation through the Ras/Raf/MEK/ERK cascade
Hematulin, A., Sagan, D., Eckardt‐Schupp, F., & Moertl, S. (2008) · Cellular Signalling · doi:10.1016/j.cellsig.2008.08.017 · Cited by 26
Novel triazole based inhibitors of Ras farnesyl transferase
Saha, A. K., Liu, L., Simoneaux, R., DeCorte, B. L., Meyer, C., Skrzat, S., Breslin, H. J., Kukla, M. J., & End, D. W. (2005) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2005.09.007 · Cited by 26
Martelli, A. M., Tabellini, G., Ricci, F., Evangelisti, C., Chiarini, F., Bortul, R., McCubrey, J. A., & Manzoli, F. A. (2011) · Advances in Biological Regulation · doi:10.1016/j.advenzreg.2011.09.019 · Cited by 23
Hong, S., Jeong, J. H., Chan, A. M.-L., & Park, J. (2013) · Experimental Cell Research · doi:10.1016/j.yexcr.2013.05.008 · Cited by 22
Inhibitors of Raf kinase and MEK signaling
Ramnath, N., & Adjei, A. A. (2007) · Update on Cancer Therapeutics · doi:10.1016/j.uct.2007.10.001 · Cited by 18
Paradoxical down-regulation of p16 mRNA with advancing age in Acute Myeloid Leukemia
de Jonge, H. J. M., Woolthuis, C. M., de Bont, E. S. J. M., & Huls, G. A. (2009) · Aging · doi:10.18632/aging.100096 · Cited by 15
Inhibitors of the ERK Mitogen-Activated Protein Kinase Cascade for Targeting RAS Mutant Cancers
Gentry, L. R., Samatar, A. A., & Der, C. J. (2013) · The Enzymes · doi:10.1016/b978-0-12-420146-0.00004-4 · Cited by 14
Kelly, J. M., Wolin, R. L., Connolly, M., Afonso, A., James, L. J., Kirshmeier, P., Bishop, W. R., & McPhail, A. T. (1998) · Bioorganic & Medicinal Chemistry · doi:10.1016/s0968-0896(98)00026-1 · Cited by 11
Building synthetic cellular organization
Polka, J., & Silver, P. A. (2013) · Molecular Biology of the Cell · doi:10.1091/mbc.e13-03-0155 · Cited by 7
Cited by
Targeting PI3K in cancer: mechanisms and advances in clinical trials
Yang, J., Nie, J., Ma, X., Wei, Y., Peng, Y., & Wei, X. (2019) · Molecular Cancer · doi:10.1186/s12943-019-0954-x · Cited by 1,520
Tewari, D., Patni, P., Bishayee, A., Sah, A. N., & Bishayee, A. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.12.008 · Cited by 642
Cell-cell communication: New insights and clinical implications
Su, J., Song, Y., Zhu, Z., Huang, X., Fan, J., Qiao, J., & Mao, F. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01888-z · Cited by 433
Myricetin: A review of the most recent research
Song, X., Tan, L., Wang, M., Ren, C., Guo, C., Yang, B., Ren, Y., Cao, Z., Li, Y., & Pei, J. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.111017 · Cited by 378
Chen, H.-T., Liu, H., Mao, M.-J., Tan, Y., Mo, X.-Q., Meng, X.-J., Cao, M.-T., Zhong, C.-Y., Liu, Y., Shan, H., et al. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1030-2 · Cited by 333
Metadata
- Authors
- Asati, V., Mahapatra, D. K., & Bharti, S. K.
- Venue
- European Journal of Medicinal Chemistry
- Publisher
- Elsevier BV
- Published
- 2016-02
- Volume
- 109
- Pages
- 314-341
- ISSN
- 0223-5234 (ISSN-L)
- OpenAlex
- W2233607184
- Cited by
- 612
- References
- 135
- FWCI
- 20.01
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.